U.S. Food and Drug Administration (OPDP / CBER Advertising and Promotional Labeling Branch) · United States
FDA Scientific Information on Unapproved Uses (SIUU) - Separation and Disclosures
Firm communications to HCPs about unapproved uses must be scientifically sound, kept separate from promotion, free of persuasive elements and accompanied by disclosures: the use is unapproved, the approved uses and labeling, study design and limitations, conflicting data and financial ties.
FDA SIUU Communications Q&A Guidance (Jan. 2025); 21 U.S.C. 352(a)
What is FDA Scientific Information on Unapproved Uses (SIUU) - Separation and Disclosures?
Firm communications to HCPs about unapproved uses must be scientifically sound, kept separate from promotion, free of persuasive elements and accompanied by disclosures: the use is unapproved, the approved uses and labeling, study design and limitations, conflicting data and financial ties. Apply to HCP-directed reprints, guideline excerpts, emails and digital resources that discuss unapproved uses of an approved prescription drug.
general_audience, general_adults_18plus, customers, health_professionals · Prescription Drug · pharma
Where does this rule apply?
United States
Which marketing channels are covered?
email, print, digital, website, trade_publication
When does this rule take effect?
2026-10-07
What does this rule require?
Firm communications to HCPs about unapproved uses must be scientifically sound, kept separate from promotion, free of persuasive elements and accompanied by disclosures: the use is unapproved, the approved uses and labeling, study design and limitations, conflicting data and financial ties.
How can marketing teams comply?
Apply to HCP-directed reprints, guideline excerpts, emails and digital resources that discuss unapproved uses of an approved prescription drug.
What is FDA Scientific Information on Unapproved Uses (SIUU) - Separation and Disclosures?
Firm communications to HCPs about unapproved uses must be scientifically sound, kept separate from promotion, free of persuasive elements and accompanied by disclosures: the use is unapproved, the approved uses and labeling, study design and limitations, conflicting data and financial ties.
Who does this rule apply to?
general_audience, general_adults_18plus, customers, health_professionals · Prescription Drug · pharma
FDA recommends that consumer-directed prescription drug promotion stating efficacy or risk numbers give absolute frequencies for the drug and control groups, use consistent formats, and avoid relative-only figures that overstate benefit.
Data in promotion that are not in the labeling, including real-world evidence, must be consistent with the approved conditions of use and be presented with the study design, limitations and context needed to avoid misleading the reader.
Unbranded disease-awareness pieces are outside the risk-disclosure rules only while they do not identify or suggest a specific product; brand cues, single-product category claims or a direct bridge to branded content make them promotion.
On character-limited platforms (paid search, short posts, SMS), a prescription drug benefit claim should be accompanied in the same unit by the established name, the most serious risks and a direct link to complete risk information, or the claim should not be made there.
Consumer-directed TV, radio and streaming ads for prescription drugs must include a major statement of the major risks presented in a clear, conspicuous and neutral manner (consumer-friendly language, audio as clear as the rest of the ad, concurrent text on TV, no distractions), plus adequate provision for full labeling.
Claims that a prescription product is safer, more effective, the only or the first compared with other products require substantial evidence, normally head-to-head data, and must be accurately qualified; compounded drugs must not be marketed as FDA-approved or equivalent to a brand.
Request a free compliance scan of your homepage and book a time with Warrant.